Arcus Biosciences Announces Five Abstracts Accepted for Presentation at AACR 2018 Annual Meeting
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that five abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, Illinois. The presentations at AACR cover three of our clinical and preclinical product candidates including our dual adenosine receptor antagonist, AB928; our PD-1 antibody, AB122; and our small molecule CD73 inhibitor, AB680. Data to be presented include: AB928:Title: Pharmacokinetic-Pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors – abstract #3769 Title: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline UpdateBusiness Wire
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire
- Top buy-rated stocks and sell-rated stocks within Health Care - Citi [Seeking Alpha]Seeking Alpha
- Investors bid Arcus Biosciences (NYSE:RCUS) up US$219m despite increasing losses YoY, taking five-year CAGR to 8.1% [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire
RCUS
Earnings
- 2/21/24 - Beat
RCUS
Sec Filings
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- 3/29/24 - Form 4
- RCUS's page on the SEC website